202 related articles for article (PubMed ID: 28671287)
1. Protein misfolding diseases: Prospects of pharmacological treatment.
Gámez A; Yuste-Checa P; Brasil S; Briso-Montiano Á; Desviat LR; Ugarte M; Pérez-Cerdá C; Pérez B
Clin Genet; 2018 Mar; 93(3):450-458. PubMed ID: 28671287
[TBL] [Abstract][Full Text] [Related]
2. Proteostasis regulators as potential rescuers of PMM2 activity.
Vilas A; Yuste-Checa P; Gallego D; Desviat LR; Ugarte M; Pérez-Cerda C; Gámez A; Pérez B
Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165777. PubMed ID: 32222543
[TBL] [Abstract][Full Text] [Related]
3. Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators.
Muntau AC; Leandro J; Staudigl M; Mayer F; Gersting SW
J Inherit Metab Dis; 2014 Jul; 37(4):505-23. PubMed ID: 24687294
[TBL] [Abstract][Full Text] [Related]
4. Protein misfolding in disease and small molecule therapies.
Gomes CM
Curr Top Med Chem; 2012; 12(22):2460-9. PubMed ID: 23339300
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Chaperoning: A Potential Treatment for PMM2-CDG.
Yuste-Checa P; Brasil S; Gámez A; Underhaug J; Desviat LR; Ugarte M; Pérez-Cerdá C; Martinez A; Pérez B
Hum Mutat; 2017 Feb; 38(2):160-168. PubMed ID: 27774737
[TBL] [Abstract][Full Text] [Related]
6. Using pharmacological chaperones to restore proteostasis.
Wang YJ; Di XJ; Mu TW
Pharmacol Res; 2014 May; 83():3-9. PubMed ID: 24747662
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders.
Hou ZS; Ulloa-Aguirre A; Tao YX
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):611-624. PubMed ID: 29851355
[TBL] [Abstract][Full Text] [Related]
8. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors.
Mouillac B; Mendre C
Handb Exp Pharmacol; 2018; 245():63-83. PubMed ID: 28939971
[TBL] [Abstract][Full Text] [Related]
10. Screening methods for identifying pharmacological chaperones.
Shin MH; Lim HS
Mol Biosyst; 2017 Mar; 13(4):638-647. PubMed ID: 28265599
[TBL] [Abstract][Full Text] [Related]
11. Protein homeostasis disorders of key enzymes of amino acids metabolism: mutation-induced protein kinetic destabilization and new therapeutic strategies.
Pey AL
Amino Acids; 2013 Dec; 45(6):1331-41. PubMed ID: 24178766
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological correction of misfolding of ABC proteins.
Rudashevskaya EL; Stockner T; Trauner M; Freissmuth M; Chiba P
Drug Discov Today Technol; 2014 Jun; 12(100):e87-94. PubMed ID: 25027379
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.
Tao YX; Conn PM
Physiol Rev; 2018 Apr; 98(2):697-725. PubMed ID: 29442594
[TBL] [Abstract][Full Text] [Related]
14. The Effects of PMM2-CDG-Causing Mutations on the Folding, Activity, and Stability of the PMM2 Protein.
Yuste-Checa P; Gámez A; Brasil S; Desviat LR; Ugarte M; Pérez-Cerdá C; Pérez B
Hum Mutat; 2015 Sep; 36(9):851-60. PubMed ID: 26014514
[TBL] [Abstract][Full Text] [Related]
15. Early Stage Discovery and Validation of Pharmacological Chaperones for the Correction of Protein Misfolding Diseases.
Aubi O; Knappskog PM; Martinez A
Methods Mol Biol; 2019; 1873():279-292. PubMed ID: 30341617
[TBL] [Abstract][Full Text] [Related]
16. Phenylketonuria as a model for protein misfolding diseases and for the development of next generation orphan drugs for patients with inborn errors of metabolism.
Muntau AC; Gersting SW
J Inherit Metab Dis; 2010 Dec; 33(6):649-58. PubMed ID: 20824346
[TBL] [Abstract][Full Text] [Related]
17. Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity.
Thellung S; Corsaro A; Nizzari M; Barbieri F; Florio T
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791416
[TBL] [Abstract][Full Text] [Related]
18. [Novel treatments in neurometabolic diseases: the importance of chaperones].
Perez B
Rev Neurol; 2018 Jun; 66(s02):S43-S46. PubMed ID: 29876912
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological Chaperones: Beyond Conformational Disorders.
Leidenheimer NJ
Handb Exp Pharmacol; 2018; 245():135-153. PubMed ID: 29071508
[TBL] [Abstract][Full Text] [Related]
20. Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis.
Marinko JT; Huang H; Penn WD; Capra JA; Schlebach JP; Sanders CR
Chem Rev; 2019 May; 119(9):5537-5606. PubMed ID: 30608666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
